Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

著者: Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, Elliott F. Winton, Hua Dong, Jun Kawashima, Julia D. Maltzman, Jean‐Jacques Kiladjian, Srđan Verstovšek - The Lancet 2017 被引用: 315